Vanda Pharmaceuticals Inc.
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
VNDA$4.08-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
| (in thousands, except for share and per share amounts) | September 30,2025 | December 31, 2024 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $70,022 | $102,316 |
| Marketable securities | 223,730 | 272,327 |
| Accounts receivable, net | 50,541 | 47,101 |
| Inventory | 2,042 | 1,726 |
| Prepaid expenses and other current assets | 21,161 | 15,420 |
| Total current assets | 367,496 | 438,890 |
| Property and equipment, net | 2,460 | 2,132 |
| Operating lease right-of-use assets | 4,368 | 5,602 |
| Finance lease right-of-use assets | 5,071 | 4,943 |
| Intangible assets, net | 108,841 | 114,096 |
| Deferred tax assets | 103,073 | 81,440 |
| Non-current inventory and other | 9,831 | 9,101 |
| Total assets | $601,140 | $656,204 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $47,619 | $39,086 |
| Product revenue allowances | 70,251 | 60,895 |
| Total current liabilities | 117,870 | 99,981 |
| Operating lease non-current liabilities | 3,419 | 4,944 |
| Finance lease non-current liabilities | 2,808 | 3,146 |
| Other non-current liabilities | 11,044 | 9,587 |
| Total liabilities | 135,141 | 117,658 |
| Commitments and contingencies (Notes 8 and 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 150,000,000 shares authorized; 59,095,630 and 58,310,644 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 59 | 58 |
| Additional paid-in capital | 718,979 | 712,706 |
| Accumulated other comprehensive income | 540 | 74 |
| Accumulated deficit | (253,579) | (174,292) |
| Total stockholders’ equity | 465,999 | 538,546 |
| Total liabilities and stockholders’ equity | $601,140 | $656,204 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.